Yttrium-90 Therapy for Liver Tumors
Author Information
Author(s): Kucuk Ozlem N, Soydal Cigdem, Lacin Seda, Ozkan Elgin, Bilgic Sadik
Primary Institution: Department of Nuclear Medicine, Faculty of Medicine, Ankara University, Ankara, Turkey
Hypothesis
The study aims to evaluate the success of selective intraarterial radionuclide therapy (SIRT) with Yttrium-90 microspheres in liver metastases of different tumors.
Conclusion
SIRT is a useful treatment method which can contribute to the lengthening of survival times in patients with primary or metastatic unresectable liver malignancies.
Supporting Evidence
- 55% of patients responded positively to the treatment.
- The mean overall survival time for responders was significantly longer than for non-responders.
- F18-FDG PET/CT was effective in evaluating treatment response.
Takeaway
Doctors used a special treatment to help people with serious liver tumors live longer. They found that this treatment worked well for many patients.
Methodology
The study evaluated clinical and follow-up data of 124 patients who underwent SIRT, with treatment response assessed using PET/CT imaging.
Potential Biases
The study may have selection bias due to the retrospective design and the inclusion of patients with different malignancies.
Limitations
The study is retrospective and has a small, heterogeneous patient population.
Participant Demographics
78 patients treated, 49 male and 29 female, mean age 62.4 years.
Statistical Information
P-Value
p = 0.04
Confidence Interval
25.63 ± 1.52 months for responders, 20.45 ± 2.11 months for non-responders
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website